CSI Market
Sign In | Register

Marker Therapeutics inc (MRKR) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access MRKR Annual Cash Flow →
The table below presents a historical view of Marker Therapeutics inc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-5.01
Depreciation & amortization0.00
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.37
Income (Loss) from Equity Method Investments0.00
Increase (Decrease) in Derivative Liabilities0.00
Adjustment Depreciation-
Gains Losses On Restructuring Of Debt-
Life Settlement Contracts Fair Value Method Gain Loss-
Gains Losses On Sales Of Assets-
Change In Unrealized Gain Loss On Fair Value Hedging Instruments-
Extinguishment Of Debt Gain Loss Income Tax-
Accretion Of Interest On Convertible Debt-
Noncash Interest And Finance Charges-
Noncash Or Part Noncash Transaction Fair Value Of Warrants Issued-
Noncash Or Part Noncash Transaction Issuance Of Additional Warrants-
Fair Value Of Common Stock Warrant Issued-
Increase Decrease In Deferred Grant-0.25
Increase Decrease Collection Of Receivables And Grant Income-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables0.25
Accounts Payable-0.28
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.46
Discontinued operations0.00
Net Cash flow from Operating Activities-5.12
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Short Term Bank Loans And Notes Payable-
Proceeds From Promissory Notes-
Subscription Revenue-
Convertible Notes Net-
Stock Issued During Period Value Other-
Debt Instrument Increase Accrued Interest-
Partners Capital Account Private Placement Of Units-
Finders Fee On Exercise Of Warrants-
Payments For Finders Fee On Exercise Of Warrants-
Proceeds From Issuance Of Common Stock And Warrants In Private Placement-
Proceeds From Issuance Of Common Stock And Warrants Net-
Proceeds From Warrants And Stock Options Exercised-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-5.12
Total Cash Flow-5.12
4 historic quarters locked

Sign in to unlock the full Marker Therapeutics inc cash flow history.

Sign In Create Free Account

About Marker Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-097262

Figures are derived from filed reports and may be restated. Historical data is subject to revision.